Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stacey A. Henning is active.

Publication


Featured researches published by Stacey A. Henning.


Mycoses | 2012

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases

Brad Moriyama; Stacey A. Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R. Penzak; Thomas J. Walsh

Triazole and imidazole antifungal agents inhibit metabolism of vincristine, leading to excess vinca alkaloid exposure and severe neurotoxicity. Recent reports of debilitating interactions between vincristine and itraconazole, as well as posaconazole, voriconazole and ketoconazole underscore the need to improve medical awareness of this adverse combination. We, therefore, undertook a comprehensive analysis of reports of adverse drug interactions (ADIs) with the combination of vincristine and azole antifungal agents, established a new classification, and provided a detailed summary of these toxicities. In patients who had sufficient data for analysis, 47 individuals were identified who had an ADI with the combination of vincristine and antifungal azoles. Median age was 8 years (1.3–68 years) with 33(70%) having a diagnosis of acute lymphoblastic leukaemia. Median time to ADI with vincristine was 9.5 days with itraconazole, 13.5 days posaconazole and 30 days voriconazole. The median number of vincristine doses preceding the ADI was 2 doses with itraconazole, 3 doses posaconazole and 2 doses voriconazole. The most common severe ADIs included gastrointestinal toxicity, peripheral neuropathy, hyponatremia/SIADH, autonomic neuropathy and seizures. Recovery from these ADIs occurred in 80.6% of patients. We recommend using alternative antifungal agents if possible in patients receiving vincristine to avoid this serious and potentially life‐threatening drug interaction.


Annals of Pharmacotherapy | 2010

High-Dose Continuous Infusion β-Lactam Antibiotics for the Treatment of Resistant Pseudomonas Aeruginosa Infections in Immunocompromised Patients

Brad Moriyama; Stacey A. Henning; Richard Childs; Steven M. Holland; Victoria L. Anderson; John C. Morris; Wyndham H. Wilson; George L. Drusano; Tom Walsh

OBJECTIVE: To report a case series of high-dose continuous infusion β-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections. CASE SUMMARY: Continuous infusion ceftazidime or aztreonam was administered to achieve target drug concentrations at or above the minimum inhibitory concentration, when possible, in 3 patients with P. aeruginosa infections. The maximal calculated target drug concentration was 100 mg/L. In the first patient, with primary immunodeficiency, neutropenia, and aggressive cutaneous T-cell lymphoma/leukemia, continuous infusion ceftazidime (6.5-9.6 g/day) was used to successfully treat multidrug-resistant P. aeruginosa bacteremia. In the second patient, with leukocyte adhesion deficiency type 1, continuous infusion aztreonam (8.4 g/day) was used to successfully treat multidrug-resistant P. aeruginosa wound infections. In the third patient, with severe aplastic anemia, continuous infusion ceftazidime (7-16.8 g/day) was used to treat P. aeruginosa pneumonia and bacteremia. In each patient, bacteremia cleared, infected wounds healed, and pneumonia improved in response to continuous infusion ceftazidime or aztreonam. DISCUSSION: Treatment strategies for multidrug-resistant P. aeruginosa infections are limited. A novel treatment strategy, when no other options are available, is the continuous infusion of existing β-lactam antibiotics to maximize their pharmacodynamic activity. High-dose continuous infusion ceftazidime or aztreonam was used for the successful treatment of resistant systemic P. aeruginosa infections in 3 chronically immunocompromised patients. CONCLUSIONS: Continuous infusion β-lactam antibiotics are a potentially useful treatment strategy for resistant P.aeruginosa infections in immunocompromised patients.


Mycoses | 2014

Emerging drugs and vaccines for Candidemia

Brad Moriyama; Lori A. Gordon; Matthew W. McCarthy; Stacey A. Henning; Thomas J. Walsh; Scott R. Penzak

Candidemia and other forms of invasive candidiasis are important causes of morbidity and mortality. The evolving challenge of antimicrobial resistance among fungal pathogens continues to highlight the need for potent, new antifungal agents. MEDLINE, EMBASE, Scopus and Web of Science searches (up to January 2014) of the English‐language literature were performed with the keywords ‘Candida’ or ‘Candidemia’ or ‘Candidiasis’ and terms describing investigational drugs with activity against Candida spp. Conference abstracts and the bibliographies of pertinent articles were also reviewed for relevant reports. ClinicalTrials.gov was searched for relevant clinical trials. Currently available antifungal agents for the treatment of candidemia are summarised. Investigational antifungal agents with potential activity against Candida bloodstream infections and other forms of invasive candidiasis and vaccines for prevention of Candida infections are also reviewed as are selected antifungal agents no longer in development. Antifungal agents currently in clinical trials include isavuconazole, albaconazole, SCY‐078, VT‐1161 and T‐2307. Further data are needed to determine the role of these compounds in the treatment of candidemia and other forms of invasive candidiasis. The progressive reduction in antimicrobial drug development may result in a decline in antifungal drug discovery. Still, there remains a critical need for new antifungal agents to treat and prevent invasive candidiasis and other life‐threatening mycoses.


Pharmacotherapy | 2013

Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications of CYP2C19 Homozygous Poor Metabolizer Genotype

Brad Moriyama; Paul Jarosinski; William D. Figg; Stacey A. Henning; Robert L. Danner; Scott R. Penzak; Alan S. Wayne; Thomas J. Walsh

There is a paucity of pharmacokinetic studies describing weight‐based dosing of intravenous voriconazole in obese patients. In this case report, we describe the pharmacokinetics of intravenous voriconazole in an obese CYP2C19 homozygous poor metabolizer and review previously reported data regarding the use of intravenous voriconazole in obese patients. A 17‐year‐old obese Hispanic male patient (body mass index 35 kg/m2) received intravenous voriconazole for the treatment of suspected aspergillosis. After 2.5 days of voriconazole 4 mg/kg intravenously every 12 hours based on adjusted body weight, the voriconazole area under the serum concentration–time curve over the course of a single (12‐hr) dosing interval and trough concentration were 86,100 ng · hr/ml and 6.2 µg/ml, respectively. Six days later, the voriconazole dosage was decreased. A trough concentration measured just before the dosage reduction (after 8.5 days of voriconazole 4 mg/kg intravenously every 12 hours based on adjusted body weight) remained elevated at 5.8 µg/ml. Genotyping revealed a CYP2C19 homozygous poor metabolizer (CYP2C19*2/*2). Voriconazole was subsequently discontinued due to QTc prolongation. These data and those from two recent publications suggest that voriconazole does not distribute extensively into human adipose tissue and that obese patients should be dosed on an adjusted body weight basis. If an obese patient dosed on total body weight is also a CYP2C19 poor metabolizer, serum voriconazole concentrations will be further elevated, potentially leading to drug‐induced toxicity.


Current Fungal Infection Reports | 2015

Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole

Brad Moriyama; Sameer S. Kadri; Stacey A. Henning; Robert L. Danner; Thomas J. Walsh; Scott R. Penzak

Voriconazole is an antifungal triazole that is the first-line agent for treatment of invasive aspergillosis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and demonstrates wide interpatient variability in serum concentrations. Polymorphisms in CYP2C19 contribute to variability in voriconazole pharmacokinetics. Here, evidence is examined for the use of voriconazole therapeutic drug monitoring (TDM) and the role of CYP2C19 genotyping in voriconazole dosing. The majority of studies exploring the impact of voriconazole TDM on efficacy and safety have found TDM to be beneficial. However, most of these studies are observational, with only one being a randomized controlled trial. High-volume multicenter randomized controlled trials of TDM are currently not available to support definitive guidelines. There is a significant relationship in healthy volunteers between CYP2C19 genotype and voriconazole pharmacokinetics, but this association is markedly less visible in actual patients. While CYP2C19 genotype data may explain variability of voriconazole serum levels, they alone are not sufficient to guide initial dosing. The timeliness of availability of CYP2C19 genotype data in treatment of individual patients also remains challenging. Additional studies are needed before implementation of CYP2C19 genotyping for voriconazole dosing into routine clinical care.


Future Microbiology | 2012

The postantifungal and paradoxical effects of echinocandins against Candida spp.

Brad Moriyama; Stacey A. Henning; Scott R. Penzak; Thomas J. Walsh

Echinocandins induce a postantifungal effect and a paradoxical effect. The postantifungal effect is a concentration-dependent process that allows for sustained kill of Candida spp. after relatively brief exposures to a compound. The paradoxical effect is growth that occurs at high echinocandin concentrations above the MIC. Paradoxical growth varies in terms of media, species, strain and type of echinocandin. The study by Shields et al. evaluated the impact of a brief exposure of caspofungin on paradoxical growth and postantifungal effects in Candida albicans isolates. In the postantifungal effect experiments, prolonged concentration-dependent killing occurred. Maximum postantifungal effects occurred with caspofungin exposures of 5 or 15 min. A brief exposure of caspofungin eliminated the paradoxical growth that was observed in the time-kill experiments. The report by Shields et al. illustrates that short exposures to an echinocandin may lead to prolonged postantifungal effects and furthers our understanding of the paradoxical effect in C. albicans.


Mycoses | 2011

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Brad Moriyama; Oluwaseun Falade-Nwulia; Janice Leung; Scott R. Penzak; Caroline JJingo; Xuan Huang; Stacey A. Henning; Wyndham H. Wilson; Thomas J. Walsh

We report a case of prolonged half-life of voriconazole due to CYP2C19*2/*2 poor metabolizer genotype in a patient receiving vincristine chemotherapy. Voriconazole was discontinued three days before start of vincristine to avoid a serious drug interaction. Therapeutic drug monitoring and genotyping are valuable tools in managing patients receiving voriconazole and vincristine.


Antimicrobial Agents and Chemotherapy | 2011

Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema

Brad Moriyama; Marisa Ditullio; Eleanor Wilson; Stacey A. Henning; Scott R. Penzak; Robert L. Danner; Gennethel Pennick; Michael G. Rinaldi; Adrian M. Zelazny; Juan Gea-Banacloche; A. John Barrett; Thomas J. Walsh

ABSTRACT Candida empyema is a serious complication of disseminated candidiasis. However, little is known about the intrapleural pharmacokinetics of echinocandins. We report the penetration of anidulafungin into the pleural fluid of a patient with Candida tropicalis empyema. The anidulafungin ratio for the area under the concentration-time curve from 0 h to the last measurement between pleural fluid and serum values was only 0.125 (12.5%), with pleural fluid concentrations ranging between 0.67 and 0.88 μg/ml.


Antimicrobial Agents and Chemotherapy | 2010

Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid

Brad Moriyama; Parizad Torabi-Parizi; Alexandra K. Pratt; Stacey A. Henning; Gennethel Pennick; Yvonne R. Shea; Sinchita Roy Chowdhuri; Michael G. Rinaldi; A. John Barrett; Thomas J. Walsh

ABSTRACT We report the penetration of liposomal amphotericin B into the pleural fluid of a patient with pulmonary zygomycosis and empyema. The ratio of area under the concentration-versus-time curve in pleural fluid (AUCpleural fluid) to that in serum (AUCserum) for liposomal amphotericin B over 24 h was 9.4%, with pleural fluid concentrations of 2.12 to 4.91 μg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema.


American Journal of Health-system Pharmacy | 2018

Stability of isoniazid injection in i.v. solutions

Jun H. Lee; Brad Moriyama; Stacey A. Henning; Robert L. Danner; Thomas J. Walsh; Scott R. Penzak; George Grimes; Gopal Potti

Purpose Results of an assessment of the chemical stability of isoniazid injection in 0.9% sodium chloride injection and 5% dextrose injection are reported. Methods Triplicate solutions of isoniazid (0.5 and 6.0 mg/mL) in the 2 diluents were prepared in ethylene and propylene copolymer i.v. containers and stored under light protection at room temperature (20–25 °C) or under refrigeration (2–8 °C). Standard aliquots were removed from each solution at time points up to 72 hours and analyzed via high‐performance liquid chromatography (HPLC). Stability was defined as retention of >90% of the initial isoniazid concentration; pH, osmolality, and visual appearance were assessed. Results Isoniazid 0.5‐ and 6.0‐mg/mL solutions in 0.9% sodium chloride injection were stable for up to 72 hours at room temperature or under refrigeration. HPLC analysis of isoniazid 0.5‐mg/mL solutions in 5% dextrose injection revealed a decrease to less than 90% of the initial concentration at 8 hours at room temperature and at 30 hours under refrigeration. Isoniazid 6.0‐mg/mL solutions in 5% dextrose injection were stable for 24 hours at room temperature and for 48 hours under refrigeration. The pH, osmolality, and visual appearance of the solutions were not affected. Conclusion Isoniazid solutions of 0.5 and 6.0 mg/mL in 0.9% sodium chloride injection were stable under light protection for up to 72 hours when stored at room temperature or under refrigeration. Isoniazid injection was less stable in 5% dextrose injection, especially at a concentration of 0.5 mg/mL at room temperature.

Collaboration


Dive into the Stacey A. Henning's collaboration.

Top Co-Authors

Avatar

Brad Moriyama

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Scott R. Penzak

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert L. Danner

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

A. John Barrett

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gennethel Pennick

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

George Grimes

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michael G. Rinaldi

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Paul Jarosinski

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Wyndham H. Wilson

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge